Trial · NCT03766893
Medication Maintenance Therapy in Community Pharmacy Settings
NCT03766893, Early phase 1, Completed, Lifespan
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Medication Maintenance Therapy in Community Pharmacy Settings. Trials, record NCT03766893. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03766893
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Medication Maintenance Therapy in Community Pharmacy Settings
- NCT number
- NCT03766893
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 11 participants, actual
- Lead sponsor
- Lifespan
- Conditions
- Opioid-use Disorder
- Interventions
- Buprenorphine / Naloxone Oral Product, injectable naltrexone, Pharmacy maintenance addiction care
- First posted
- 2018-12-06
- Last updated
- 2019-08-01
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pharmacists' dispensing of MAT medications | up to one month | Measured by the number of MAT medications dispensed from a study pharmacy according to the pharmacy records, over the one month pilot period. |
| Primary | Pharmacists' monitoring of MAT care | up to one month | Measured by the number of toxicological drug screens performed at a study pharmacy over the one month pilot period. |
| Primary | Pharmacist-reported feasibility of executing the collaborative pharmacy practice: agreement for MAT: Likert scale | up to one month | 7-point Likert scale item assessing the pharmacist's view of the overall model feasibility. The item asks: How acceptable is providing buprenorphine/Suboxone care at the pharmacy? With responses ranging from 1 to 7 as: 1. totally unacceptable 2. unacceptable 3. slightly unacceptable 4. neutral 5. slightly acceptable 6. acceptable 7. perfectly acceptable Higher scores represent better outcome (i.e., endorsement of acceptability of the model), according to the pharmacists. |
| Primary | Patient acceptability of pharmacy-provided MAT care: Likert scale | up to one month | 7-point Likert scale item assessing overall acceptability of the pharmacy MAT model. The item asks: How acceptable is going to the pharmacy for your buprenorphine/Suboxone care? With responses ranging from 1 to 7 as: 1. totally unacceptable 2. unacceptable 3. slightly unacceptable 4. neutral 5. slightly acceptable 6. acceptable 7. perfectly acceptable Higher scores represent better outcome (i.e., high endorsement of acceptability of the model), according to the patients. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03766893
GET https://conductscience.org/api/trials/v1/NCT03766893/registered